Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study.
Halet TürkantozChristoph KönigsPaul KnöblRobert KlamrothKatharina HolsteinAngela Huth-KühneJürgen HeinzHermann EichlerAndreas TiedePublished in: Journal of thrombosis and haemostasis : JTH (2019)
Cross-reacting inhibitors should be considered when choosing a treatment for bleeding patients with AHA. Cross-reactivity is frequent in patients with anti-human FVIII titers of >100 BU/mL.